Retargetting T cells to generate novel cancer therapeutics v.01
Research type
Research Study
Full title
A study to investigate and optimise novel T cell therapeutics for cancer
IRAS ID
350784
Contact name
John S Bridgeman
Contact email
Sponsor organisation
ImmunoKey Ltd.
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
We are investigating methods to develop new and innovative immune based therapies for cancer where white blood cells are reprogrammed to attack and kill cancer cells. Such therapies are now becoming recognized as game-changers for a number of blood cancers. We are investigating methods to broaden their applicability in other cancers. New treatments for cancer are required as the incidence of cancer is predicted to increase over the coming decades despite new emerging therapies. It is hoped the treatment we are developing will be applicable to many people, with otherwise drug unresponsive cancers.Samples will be sourced from biobanks and normal healthy donated material, with no participants undergoing any intervention directly for this project alone.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
24/PR/1550
Date of REC Opinion
23 Dec 2024
REC opinion
Favourable Opinion